Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.

Also called NCT01047566

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 183 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01047566
  • EudraCT 2009-018215-53
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01047566. Randomized; no masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)
Acronym
AFRODITE
Intervention (Drug)
Dronedarone
Intervention (Drug)
Beta blocker or calcium antagonist or digoxin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01047566
Content hash
941d9c1960f31f5e5bc85b22b82c3a0aef18d6cb9a44ac7e6d34649607f94b33